TNF
TNF-α is a type II transmembrane protein with an intracellular N terminus. It has signalling potential both as a membrane-integrated protein and as a soluble cytokine released after proteolytic cleavage; its soluble form being a non-covalently bound trimer of 17 kDa components. There are two TNF receptors, TNFRI, which is found on most cells in the body, and TNFRII, which is primarily expressed on haemopoietic cells. TNFRI is activated by soluble ligand, TNFRII mainly by the membrane-integrated form. TNF receptors are also shed and act as soluble TNFbinding proteins, inhibiting TNF-α bioactivity by competing with cell surface receptors for free ligand. Ligand binding to TNFR1 induces a range of inflammatory mediators and growth factors via activation of the AP-1 transcription factors or IKβ kinases that, in turn, activate NF-κB. NF-κB activation also importantly induces negative regulators of apoptosis such as c-FLIPL, Bcl-2 and superoxide dismutase.
If NF-κB activation is not successful then apoptosis is mediated through caspase 8 and, via accumulation of intracellular reactive oxygen, sustained Jun N-terminal kinase activation and mitochondrial pathways. Ligand binding to TNFRII leads to activation of NF-κB, JNK, p38 MAPK, ERK and PI3K pathways, but the biological role of this receptor is still not fully understood. Many pathological situations, including cancer, are characterised by an imbalance between survival and apoptosis signals, but TNF-α is also critical to cellular communication during host defence, inflammation and organogenesis.
References
1.Balkwill F. Cancer Metastasis Rev. 2006;25(3):409–416.
If NF-κB activation is not successful then apoptosis is mediated through caspase 8 and, via accumulation of intracellular reactive oxygen, sustained Jun N-terminal kinase activation and mitochondrial pathways. Ligand binding to TNFRII leads to activation of NF-κB, JNK, p38 MAPK, ERK and PI3K pathways, but the biological role of this receptor is still not fully understood. Many pathological situations, including cancer, are characterised by an imbalance between survival and apoptosis signals, but TNF-α is also critical to cellular communication during host defence, inflammation and organogenesis.
References
1.Balkwill F. Cancer Metastasis Rev. 2006;25(3):409–416.
Apoptosis
TNF
-
Zigakibart
产品货号 : M37285
cas no: 2642175-46-8
Zigakibart (BION-1301) 是一种 IgG4-kappa、抗 TNFSF13 (肿瘤坏死因子 (TNF) 超家族成员 13、APRIL、CD256) 人源化单克隆抗体。 Zigakibart 具有抗炎活性。 -
Tulisokibart
产品货号 : M37264
cas no: 2648504-55-4
Tulisokibart (PRA023) 是人源化后的小鼠 IgG1-κ 型抗体,靶向 TNFSF15/TL1A。Tulisokibart 可用于多种炎症/纤维化疾病的研究,例如克罗恩病 (Crohn's Disease, CD)。 -
TNF-α-IN-9
产品货号 : M36913
cas no: 2054199-25-4
TNF-α-IN-9 (compound 48) 是 NDM-1 inhibitor-3 (HY-150758) 的类似物。TNF-α-IN-9 是一种 TNF-α 抑制剂。TNF-α-IN-9 显示低抑制活性。 -
Atibuclimab
产品货号 : M36910
cas no: 2417175-94-9
Atibuclimab 是一种针对 CD14 的嵌合单克隆抗体,由小鼠可变区和人类 IgG4 Fc 区组成。Atibuclimab 可用于肌萎缩侧索硬化症的研究。Atibuclimab 可减轻 LPS 诱导的症状,并强烈抑制 LPS 诱导的促炎细胞因子释放,同时仅延迟抗炎细胞因子可溶性 TNF 受体 I 型和 IL-1 受体拮抗剂的释放。 -
Ragifilimab
产品货号 : M36831
cas no: 2207590-51-8
Ragifilimab (INCAGN-1876) 是一种靶向糖皮质激素诱导的 TNFR 相关蛋白 (GITR) 的激动剂单克隆抗体。Ragifilimab 可用于晚期或转移性实体瘤研究。